W World Corp.
WWHC
Other OTC0.80
USD
-0.20
- -
ISIN
US92942B1035
Return %
Stock
S&P500
1Y
-23.08
18.21
3Y
-60.40
64.38
5Y
-48.72
72.43
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Eric W. Fangmann
- Full Time Employees
- 2
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 3609 Hammerkop Drive North Las Vegas NV United States of America 89084
- IPO Date
- Aug 5, 1983
- Website
- pharmoscorp.com
- Similar Companies
- Business
- W World Corp. (WWHC) operates as a biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics targeting metabolic and nervous system disorders, including those of the brain-gut axis; pain and inflammation; autoimmune conditions; gout; irritable bowel syndrome; oncology; immunology; ophthalmology; infectious diseases; and central nervous system disorders. The company offers lead clinical-stage compounds such as Levotofisopam, a non-sedating agent for gout treatment, and Dextofisopam, a non-serotonergic agent that has completed Phase IIa and Phase IIb trials for irritable bowel syndrome; it also provides oncology medicines including hormone therapy, targeted therapies and immunotherapies, antibiotics for bacterial infections, antimalarials, cancer maintenance medications, and generics like Lisinopril (Prinivil/Zestril) for blood pressure management, heart failure and kidney protection. Founded in 1990 and headquartered at 3609 Hammerkop Drive in North Las Vegas, Nevada, W World Corp. maintains operations primarily in the United States with a pipeline encompassing preclinical and clinical candidates; the company emphasizes sustainable development goals such as good health, innovation, responsible production and partnerships, alongside ethical supply chain management and third-party risk mitigation. Recent activities reflect a strategic pivot toward diversified pharmaceutical offerings, including emphasized cancer diagnostics, diabetes management and expanded biotech solutions in oncology and immunology as highlighted on its website; no major acquisitions, funding rounds or partnerships have been publicly reported in the last one to two years.